- Have measures been implemented to achieve the objectives in the EU Drugs Strategy and its Action Plan?
- How effective have the implemented measures been?
- What other steps should be taken to improve the drugs situation in the European Union?
A mandatory public consultation was conducted to inform the Mid-Term Assessment of the EU Drugs Strategy 2013-2020 and the final evaluation of the EU Action Plan on Drugs 2013-2016. This document reports on the consultation's results.
Table of Contents
Demographic profile of consultation respondents
Other ad-hoc contributions
Analysis framework for the public consultation
Public consultation questionnaire
The research described in this report was prepared for the European Commission and conducted by RAND Europe.
This report is part of the RAND Corporation research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.